- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05285618
The Perceptual Experience of Argus II Users
Predicting the Perceptual Experience of Argus II Retinal Prosthesis System Users
Study Overview
Detailed Description
This study focuses on two experiments involving blind participants implanted with the Argus II retinal prosthesis:
Experiment 1: Paired-Electrode Phosphene Perception The study retrospectively analyzes 3548 phosphene drawings made by three participants. We investigate the impact of single- and paired-electrode stimulation on phosphene shape (area, perimeter, major/minor axis length) and the number of perceived phosphenes. Neuroanatomical parameters, including electrode-retina distance, electrode-fovea distance, and electrode-electrode distance (both along-axon and between-axon), are correlated with these outcomes. Statistical analyses include linear regression and partial correlation to examine the relationship between stimulation parameters and phosphene perception.
Experiment 2: Performance Factors in Argus II Prostheses This study explores the factors contributing to high current amplitude thresholds and poor spatial resolution in three participants. We measure current amplitude thresholds and two-point discrimination (the ability to distinguish stimulation on one versus two electrodes). Data from psychophysical experiments and simulations are analyzed to identify the roles of axonal stimulation, electrode lift, and retinal damage in limiting device performance.
These experiments aim to advance the understanding of epiretinal stimulation and inform the development of future retinal prostheses with improved spatial resolution and sensitivity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93106
- University of California, Santa Barbara
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan, Ann Arbor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Subject must be at least 25 years of age;
- Subject has been implanted with the Argus II system;
- Subject's eye has healed from surgery and the surgeon has cleared the subject for programming;
- Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback);
- Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days;
- Subject is capable of understanding patient information materials and giving written informed consent;
- Subject is able to walk unassisted.
Exclusion criteria:
- Subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe;
- Sighted controls: Subject has a history of motion sickness or flicker vertigo
- Subject does not speak English;
- Subject has language or hearing impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Argus II users
This Basic Experimental Studies Involving Humans (BESH) study investigates phosphene perception and performance factors in blind participants implanted with the Argus II retinal prosthesis system.
Using paired-electrode stimulation, we analyze how phosphene shape and number are influenced by neuroanatomical factors, stimulus parameters, and spatial offsets.
Additionally, we examine the causes of high current thresholds and limited spatial resolution, which impede pattern vision in Argus II devices.
This research aims to provide insights for optimizing stimulation strategies and improving retinal prosthesis design.
|
Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Phosphenes Perceived
Time Frame: during single-session testing
|
Number of phosphenes perceived in response to paired-electrode stimulation across 5 spatial distances and 7 temporal interpulse delays.
Phosphenes are brief sensations of light or visual flashes that occur in the absence of an external light source.
A response is counted as a phosphene if the participant reports any visual sensation consistent with a flash of light.
|
during single-session testing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael Beyeler, PhD, University of California, Santa Barbara
Publications and helpful links
General Publications
- Yucel EI, Sadeghi R, Kartha A, Montezuma SR, Dagnelie G, Rokem A, Boynton GM, Fine I, Beyeler M. Factors affecting two-point discrimination in Argus II patients. Front Neurosci. 2022 Aug 24;16:901337. doi: 10.3389/fnins.2022.901337. eCollection 2022.
- Hou Y, Nanduri D, Granley J, Weiland JD, Beyeler M. Axonal stimulation affects the linear summation of single-point perception in three Argus II users. J Neural Eng. 2024 Apr 8;21(2):026031. doi: 10.1088/1741-2552/ad31c4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R00EY029329 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa
-
University of GöttingenRecruitingX-Linked Retinitis Pigmentosa (XLRP) | RP2-associated Retinitis Pigmentosa | Retinitis Pigmentosa 2Germany
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
University of Colorado, DenverEnrolling by invitationPosterior Column Ataxia With Retinitis PigmentosaUnited States
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
Oslo University HospitalActive, not recruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCCompletedX-Linked Retinitis PigmentosaCanada, United States, Israel, United Kingdom, France, Belgium, Italy, Netherlands, Switzerland, Spain, Denmark
-
Beacon TherapeuticsActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom, Australia, Canada
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
Janssen Research & Development, LLCCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
Clinical Trials on Argus II
-
Mayo ClinicSecond Sight Medical ProductsCompleted
-
Second Sight Medical ProductsWithdrawn
-
Second Sight Medical ProductsCompleted
-
Second Sight Medical ProductsNational Eye Institute (NEI)CompletedRetinitis PigmentosaUnited States, United Kingdom, France, Mexico, Switzerland
-
Second Sight Medical ProductsCompletedAge Related Macular DegenerationUnited Kingdom
-
Duke UniversityCompleted
-
Second Sight Medical ProductsCompletedRetinitis PigmentosaUnited States
-
KOS Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Prediabetes | Diabetes Mellitus, Type 1 DiabetesUnited States
-
Jewish General HospitalSunnybrook Health Sciences Centre; Center Hospitalier de Fleurimont,Sherbrooke...UnknownStress Urinary IncontinenceCanada
-
The San Francisco Clinical Research CenterUnknown